Skip to content

Serotonin: all studies

Page 40 of 400: studies 391 to 400 of 3,999, newest first. Back to the serotonin overview

Research

Overcoming Depression with 5-HT2A Receptor Ligands

International Journal of Molecular Sciences December 21, 2021 Agata Zięba, Piotr Stępnicki, Dariusz Matosiuk et al. 55 citations

Depression is a multifactorial disorder that affects millions of people worldwide, and none of the currently available therapeutics can completely cure it. Thus, there is a need for developing novel, potent, and safer agents. Recent medicinal chemistry findings on the structure and function of the serotonin 2A (5-HT2A) receptor facilitated design and discovery of novel compounds with...

DOI: 10.3390/ijms23010010 (opens in new tab) Virtual screening Receptor Depression economics Antidepressant +3

Pharmacologic analysis of non-synonymous coding 5-HT2A SNPs reveals alterations psychedelic drug potencies and efficacies

bioRxiv Preprint Server December 9, 2021 Gavin P. Schmitz, Manish K. Jain, Samuel T. Slocum et al. preprint

Serotonin (5-Hydroxytryptamine; 5-HT) 2A receptor (5-HT2AR) signaling is essential for the actions of classical psychedelic drugs. In this study, we examined whether random sequence variations in the gene (single nucleotide polymorphisms, SNPs) encoding the 5-HT2AR affect the signaling of four commonly used psychedelic drugs. We examined the in vitro pharmacology of seven non-synonymous SNPs,...

New insights into methoxetamine mechanisms of action: Focus on serotonergic 5-HT2 receptors in pharmacological and behavioral effects in the rat.

Experimental Neurology November 1, 2021 Matteo Marti, Giuseppe Talani, Cristina Miliano et al. 6 citations

Methoxetamine (MXE) is a dissociative substance of the arylcyclohexylamine class that has been present on the designer drug market as a ketamine-substitute since 2010. We have previously shown that MXE (i) possesses ketamine-like discriminative and positive rewarding effects in rats, (ii) affects brain processing involved in cognition and emotional responses, (iii) causes long-lasting...

Serotonergic Psychedelics in Neural Plasticity

Frontiers in Molecular Neuroscience October 12, 2021 Kacper Łukasiewicz, Jacob J. Baker, Yi Zuo et al. 32 citations

Psychedelics, compounds that can induce dramatic changes in conscious experience, have been used by humans for centuries. Recent studies have shown that certain psychedelics can induce neural plasticity by promoting neurite growth and synapse formation. In this review, we focus on the role of classical serotonergic psychedelics in neural plasticity and discuss its implication for their...

5-HT2 Receptor Subfamily and the Halogen Bond Promise

Journal of chemical information and modeling October 7, 2021 A. Fierro, Douglas J. Matthies, B. Cassels et al.

The binding of C-4-halogenated 1-(4-X-2,5-dimethoxyphenyl)-2-aminopropane (DOX) serotonin agonist psychedelics at all three 5-HT2 receptor subtypes is up to two orders of magnitude stronger for X = Cl, Br, or I (but not F) than when C-4 bears a hydrogen atom and more than expected from their hydrophobicities. Our docking and molecular dynamics simulations agree with the fact that increasing the...

Neuropsychological Functioning in Users of Serotonergic Psychedelics – A Systematic Review and Meta-Analysis

Frontiers in Pharmacology September 16, 2021 Lukas A Basedow, Thomas Riemer, Simon Reiche et al. 16 citations

Background: Serotonergic psychedelics (SPs) like LSD, psilocybin, DMT, and mescaline are a heterogeneous group of substances that share agonism at 5-HT 2a receptors. Besides the ability of these substances to facilitate profoundly altered states of consciousness, persisting psychological effects have been reported after single administrations, which outlast the acute psychedelic effects. In...

The Potential Role of Serotonergic Hallucinogens in Depression Treatment

Life July 29, 2021 Dominika Psiuk, Emilia Nowak, Krystian Cholewa et al. 13 citations

Due to an increasing number of depression diagnoses and limited effective treatments, researchers continue to explore novel therapeutic strategies for this disorder. Recently, interest has revolved around the use of serotonergic psychedelics to reduce the symptoms of depression. In this systematic review, we summarize the currently available knowledge on the safety and efficacy of psychedelic...

Serotonin Heteroreceptor Complexes and Their Integration of Signals in Neurons and Astroglia—Relevance for Mental Diseases

Cells July 27, 2021 Dasiel O Borroto-Escuela, Patrizia Ambrogini, Manuel Narváez et al. 29 citations

The heteroreceptor complexes present a novel biological principle for signal integration. These complexes and their allosteric receptor–receptor interactions are bidirectional and novel targets for treatment of CNS diseases including mental diseases. The existence of D2R-5-HT2AR heterocomplexes can help explain the anti-schizophrenic effects of atypical antipsychotic drugs not only based on...

DOI: 10.3390/cells10081902 (opens in new tab) Relevance law Cognitive science

Role of the 5-HT2A Receptor in Acute Effects of LSD on Empathy and Circulating Oxytocin

Frontiers in Pharmacology July 13, 2021 Friederike Holze, Isidora Avedisian, Nimmy Varghese et al. 66 citations

The psychedelic lysergic acid diethylamide (LSD) has experienced a revival in research, including clinical trials that evaluate LSD-assisted psychotherapy. LSD induces perceptual alterations and influences emotion processing in ways that may support psychotherapy. Here, we investigated the effects of LSD on emotional empathy and mediating role of the serotonin 5-hydroxytryptamine-2A (5-HT 2A )...

Serotonin toxicity of serotonergic psychedelics

Psychopharmacology July 12, 2021 Benjamin Malcolm, Kelan Thomas 131 citations

RationaleIn recent years, psychedelic substances with serotonergic mechanisms have accumulated substantial evidence that they may provide therapeutic benefits for people suffering with psychiatric symptoms. Psychiatric disorders targeted by these psychedelic-assisted therapies are managed with serotonergic drugs like selective serotonin reuptake inhibitors (SSRIs) as the current standard of...